Tag
The phase 3 VISIONARY trial establishes sibeprenlimab as a promising therapy in IgA nephropathy, significantly stabilizing eGFR decline and reducing kidney-function deterioration over 24 months with a favorable safety profile.
Interim analysis of a phase 3 trial demonstrates povetacicept’s efficacy in reducing proteinuria and pathological markers in IgA nephropathy, with a favorable safety profile.
Ravulizumab, a terminal complement C5 inhibitor, significantly reduces proteinuria in adults with IgA nephropathy, demonstrating safety and biomarker improvements in phase 2 and 3 trials, highlighting its therapeutic potential.
The Phase 3 VISIONARY trial interim analysis demonstrates that sibeprenlimab, a monoclonal antibody targeting APRIL, significantly reduces proteinuria and pathogenic IgA1 in patients with IgA nephropathy, offering a promising upstream thera
A prespecified interim analysis of a phase 3 trial shows atacicept produced a 45.7% proteinuria reduction versus 6.8% with placebo at 36 weeks. Phase 2 data for sibeprenlimab, cemdisiran, and felzartamab also show promising antiproteinuric
Recent clinical trials of APRIL-targeted monoclonal antibodies—zigakibart, sibeprenlimab, and telitacicept—demonstrate safety and significant proteinuria reduction in IgA nephropathy and IgA vasculitis nephritis, offering promising disease-
